Information Provided By: 
Fly News Breaks for October 14, 2019
FOLD
Oct 14, 2019 | 07:09 EDT
The 36% decline in shares of Amicus Therapeutics since July 15 has created a "compelling opportunity" for investors with a 12-plus month investment horizon, H.C. Wainwright analyst Debjit Chattopadhyay tells investors in a research note. The company has an "established and growing" commercial franchise around Galafold, which can be leveraged upon for the future launch of AT-GAA, says the analyst. Chattopadhyay keeps a Buy rating on Amicus with an $18 price target.
News For FOLD From the Last 2 Days
There are no results for your query FOLD
